Callum BaylisDuffield - Plandai Biotech Chief Pres

All Insiders . USA . 
Stock . Plandai Biotech . Stakeholders . Insider . Callum BaylisDuffield
PLPL Stock  USD 0.0002  0.0001  100.00%   

Insider

Callum BaylisDuffield is Chief Pres of Plandai Biotech
Age 38
Phone44 91 7900 9829
Webhttps://www.plandaibiotech.com

Plandai Biotech Management Efficiency

The company has return on total asset (ROA) of (0.2096) % which means that it has lost $0.2096 on every $100 spent on assets. This is way below average. Plandai Biotech's management efficiency ratios could be used to measure how well Plandai Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Michelle DalyNasdaq Inc
47
Jason ForcierVertiv Holdings Co
48
Rainer StillerVertiv Holdings Co
N/A
Brian MBAChoice Hotels International
N/A
Anand SanghiVertiv Holdings Co
52
Luke LarsonAxon Enterprise
43
Giordano AlbertazziVertiv Holdings Co
57
Patrick SmithAxon Enterprise
53
Joseph DokkumVertiv Holdings Co
66
Keith EsqMicrosoft
N/A
Edward CFANasdaq Inc
N/A
Alfonso VillanuevaPayPal Holdings
N/A
Scott CrippsVertiv Holdings Co
N/A
John ZeccaNasdaq Inc
56
Donna VieiraChoice Hotels International
55
Andrew KlausVertiv Holdings Co
54
Stephen LiangVertiv Holdings Co
65
Prof DallyNVIDIA
63
Elizabeth RedmondChoice Hotels International
60
Andrew ColeVertiv Holdings Co
54
Noha AbdallaChoice Hotels International
46
Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States. Plandai Biotech [PLPL] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Asset-0.21

Plandai Biotech Management Team

Elected by the shareholders, the Plandai Biotech's board of directors comprises two types of representatives: Plandai Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plandai. The board's role is to monitor Plandai Biotech's management team and ensure that shareholders' interests are well served. Plandai Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plandai Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Callum BaylisDuffield, Chief Pres
Roger BaylisDuffield, Chairman of the Board, CEO, CFO
Ezra Jones, Vice President of Sales and Marketing

Plandai Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Plandai Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.21
Operating Margin(12.22) %
Current Valuation236.87 K
Shares Outstanding263.19 M
Price To Earning(0.32) X
Price To Sales1.04 X
Revenue411.99 K
Gross Profit(768.91 K)
EBITDA(2.1 M)
Net Income(4.01 M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Plandai Pink Sheet

Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY